[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda di Servizi alla Persona di Pavia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,63,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100621960","beneficial-effects-of-supplementation-with-cronilief-palmitoylethanolamide-phospholipids-in-diabetic-subjects-with-neuropathic-pain-100621960",false,"NCT07377409","Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.","Randomised, Placebo-controlled Study to Evaluate the Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids), in Addition to Standard Therapy, in Diabetic Subjects With Neuropathic Pain.","Inclusion Criteria:\n\n* Satisfactory metabolic compensation;\n* Presence of moderate symptoms of painful diabetic neuropathy as assessed by the LANSS questionnaire (score ≥12);\n* Taking antidiabetic drugs except insulin;\n* Subjects willing and able to comply with scheduled study visits, the treatment plan, and all procedures outlined in the study.\n\nExclusion Criteria:\n\n* Previous intolerance to a component of the nutraceuticals tested;\n* Individuals with type I diabetes;\n* Uncontrolled diabetes, severe cardiovascular and cerebrovascular diseases;\n* Severe neuropathic symptoms as indicated by the LANSS score;\n* Individuals undergoing insulin treatment;\n* Peripheral neuropathy due to diseases other than diabetes mellitus;\n* History of malignant neoplasm in the 5 years prior to enrolment in the study;\n* Serious neurological, psychological or psychiatric disorders;\n* Clinical signs or history of significant impairment of hepatic or renal function, peptic ulcer or coagulation disorders;\n* Any clinically relevant or unstable disease (e.g., active malignancies, immune system disorders) whose sequelae or treatments could contraindicate participation in the study or interfere with the study's evaluation parameters, in the investigator's judgement; Any disease that could significantly affect the study's outcome, including, but not limited to, chronic medical conditions, psychological disorders, or substance abuse;\n* Alcohol or drug abuse;\n* Women of childbearing age who do not use established contraceptive methods;\n* Pregnancy and breastfeeding.","ALL","18 Years","65 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the potential benefit of an oral nutritional supplement based on CRONILIEF™ (Palmitoylethanolamide Phospholipids) in diabetic subjects with neuropathic pain, compared to a placebo.",[27,28,29],"Neuropathic Pain Management","Diabetic Neuropathies, Painful","Palmitoylethanolamide","NOT_YET_RECRUITING","2026-02-12",{"date":33,"type":34},"2026-02-17","ACTUAL",{"date":36,"type":21},"2026-09-15",{"date":38,"type":21},"2027-01-15",{"name":40,"class":41},"Azienda di Servizi alla Persona di Pavia","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":4},"100589501","berbevis-dose-finding-study-in-subjects-with-impaired-fasting-glucose-100589501","NCT06955234","Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose","Berbevis Project: Multitarget Dose-finding Study","BERBEVIS-DFG-0","Inclusion Criteria:\n\n* fasting blood glucose between 100 and 126 mg\u002Fdl\n* BMI between 25 and 35 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Fasting blood glucose below 100 mg\u002Fdl\n* BMI \\\u003C 25 or \\> 35 kg\u002Fm\\^2",{"count":51,"type":21},90,[24],"Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg\u002FdL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.",[55],"Impaired Fasting Glucose (IFG)","2025-11-23",{"date":58,"type":34},"2025-11-25",{"date":60,"type":21},"2026-06-15",{"date":36,"type":21},{"name":40,"class":41},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":4},"100588553","evaluation-of-a-dietary-supplement-containing-melissa-officinalis-formulated-in-phospholipids-on-mood-well-being-and-cortisol-modulation-100588553","NCT06942897","Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation","Pilot Study for the Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Healthy volunteers as assessed by medical history and physical examination\n* Willingness to comply with the study procedures\n\nExclusion Criteria:\n\n* Current use of medications or supplements that may affect mood or cortisol levels\n* Known allergy or sensitivity to Melissa officinalis or phospholipids\n* History of psychiatric disorders (e.g., major depression, anxiety disorders)\n* Significant comorbidities (e.g., cardiovascular, hepatic, renal diseases)\n* Pregnant or breastfeeding women\n* Participation in another clinical trial in the past 30 days",true,{"count":72,"type":21},40,[24],"This is a randomized, double-blind, placebo-controlled pilot study designed to evaluate the effect of an oral nutritional supplement containing Melissa officinalis formulated in phospholipids on mood and cortisol levels in healthy adults. Participants will be randomly assigned to receive either the active supplement or a placebo daily for 3 weeks. The primary outcome measures include changes in mood well-being, perceived stress, and salivary cortisol levels. The study aims to assess both efficacy and safety of the supplement in modulating stress response and emotional balance.",[76,77,78],"Stress","Mood Disorders","Emotional Well-being",{"date":58,"type":34},{"date":60,"type":21},{"date":36,"type":21},{"name":40,"class":41},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":111,"locationsCount":4},"100589409","evaluate-the-beneficial-effects-of-an-oral-nutritional-supplement-based-on-leonurus-cardiaca-for-the-improvement-of-mood-and-anxiety-100589409","NCT06954038","Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety","A Randomized, Double Dummy, Placebo-controlled Pilot Study to Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety","LEONORUS","Inclusion Criteria:\n\n* Aged 20 to 50 years\n* Diagnosis of a generalised anxiety disorder (GAD), with manifestations occurring for \\>= 6 months that include excessive worry, poor concentration, restlessness, muscle tension, irritability, fatigue and difficulty sleeping\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding\n* Use of hormonal contraceptives in the last 3 months\n* Current diagnosis of major psychiatric disorders (e.g., major depressive disorder, severe anxiety disorders, schizophrenia, bipolar disorder)\n* Known endocrine disorders (e.g., hypothyroidism, hyperthyroidism, diabetes)\n* Use of medications that could affect mood or the menstrual cycle (e.g., SSRIs, anxiolytics, antipsychotics)\n* Severe hepatic or renal impairment\n* Any other serious or unstable medical condition that, in the investigator's judgment, could interfere with study participation","20 Years","50 Years",{"count":94,"type":21},60,[24],"This study aims to evaluate the efficacy and safety of Leonurus cardiaca extract in reducing anxiety symptoms in adults with Generalized Anxiety Disorder (GAD). Sixty drug-free participants aged 20-50 years with a diagnosis of GAD will be randomly assigned to receive either Leonurus cardiaca extract or placebo for 30 days. The primary outcome is the reduction in anxiety symptoms assessed by the SCAG scale. Secondary outcomes include changes in quality of life (SF-12), perceived stress (PSQ), anxiety severity (HAM-A), and anthropometric measures. Safety will be assessed through liver, kidney, and thyroid function tests. Assessments will be conducted at baseline, day 14, and day 30.",[98],"General Anxiety Disorder",[100,101,102,103,104,105,106,107],"Leonurus cardiaca","Herbal extract","Anxiety","SCAG scale","Herbal remedy for GAD","HAM-A","PSQ","SF-12",{"date":58,"type":34},{"date":60,"type":21},{"date":36,"type":21},{"name":40,"class":41},""]